Protara Therapeutics Inc. (TARA)
3.44
-0.30 (-8.02%)
At close: Mar 03, 2025, 3:59 PM
3.23
-6.24%
After-hours: Mar 03, 2025, 07:17 PM EST
Protara Therapeutics Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2.95M | n/a | n/a |
| Cost of Revenue | 341K | 247K | 1.17M | 196K | 16K | 115K | 148K | 123K | 57K | n/a | 27K | 57K |
| Gross Profit | -341K | -247K | -1.17M | -196K | -16K | -115K | -148K | -123K | -57K | 2.95M | -27K | -57K |
| Operating Income | -43.61M | -67.06M | -47.49M | -34.44M | -15.25M | -26.08M | -30.36M | -28.7M | -20.87M | -7.58M | -7.12M | -8M |
| Interest Income | 2.73M | 1.11M | 237K | 466K | n/a | n/a | n/a | n/a | n/a | n/a | 4K | 20K |
| Pretax Income | -40.42M | -65.95M | -47.25M | -33.98M | -14.99M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Net Income | -40.42M | -64.81M | -47.13M | -33.51M | -14.73M | -25.44M | -29.96M | -28.53M | -21.38M | -3.34M | -7.91M | -7.97M |
| Selling & General & Admin | 18.62M | 20.74M | 26.4M | 22.46M | 8.82M | 10.57M | 8.53M | 9.71M | 8.43M | 4.1M | 3.1M | 2.03M |
| Research & Development | 24.79M | 16.81M | 21.09M | 11.98M | 6.44M | 15.51M | 21.69M | 18.87M | 12.38M | 6.43M | 3.99M | 5.91M |
| Other Expenses | n/a | 29.52M | n/a | n/a | n/a | 207K | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.21M | 28.58M | 20.81M | 10.53M | 7.09M | 7.94M |
| Interest Expense | n/a | 1.14M | 1.74M | 34K | n/a | n/a | 259K | 193K | 144K | 857K | 861K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | 8.42M | -123K | -57K | n/a | n/a | n/a |
| Cost & Expenses | 43.61M | 37.55M | 47.49M | 34.44M | 15.25M | 26.08M | 30.36M | 28.7M | 20.87M | 10.53M | 7.12M | 8M |
| Income Tax | n/a | -1.14M | -117K | -466K | -262K | 5.35M | 657K | 372K | -363K | 5.09M | n/a | n/a |
| Shares Outstanding (Basic) | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.6K | 76.61K | 374.85K | 374.85K |
| Shares Outstanding (Diluted) | 11.33M | 11.26M | 11.23M | 7.23M | 64.44K | 2.56M | 431.86K | 414.04K | 411.6K | 76.61K | 374.85K | 374.85K |
| EPS (Basic) | -3.57 | -5.76 | -4.2 | -4.63 | -228.6 | -9.93 | -69.38 | -68.9 | -51.94 | -43.62 | -37.43 | -37.62 |
| EPS (Diluted) | -3.57 | -5.76 | -4.2 | -4.63 | -228.6 | -9.93 | -69.38 | -68.9 | -51.94 | -43.62 | -37.43 | -37.62 |
| EBITDA | -43.27M | -64.57M | -46.09M | -33.78M | -7.81M | -20.61M | -29.82M | -28.4M | -21.32M | -2.45M | -7.02M | -7.91M |
| Depreciation & Amortization | 341K | 247K | 1.17M | 196K | 16K | 115K | 148K | 123K | 57K | 30K | 27K | 57K |